The
- This is very positive news for Bio Vitos Pharma. This enables strong protection for our iron succinate product Succifer which we are developing and increases our future revenue potential. Via
The clinical trials conducted by DBP show that iron succinate significantly improves iron absorption, iron saturation and iron storages in patients with heart failure and iron deficiency.
Iron succinate is a less expensive alternative to the successful product Ferinject (which - as the name suggests - is administered intravenously). In 2022, the global sales of Ferinject amounted to approximately
For further information, contact:
Jesper Birgemo, CEO
Tel: +46 (0) 70 895 39 34
About
Bio Vitos Pharma develops, produces, and commercializes iron succinate for the treatment of iron deficiency within the parent company as well as a service for close-to-patient detection of hemolysis in blood samples within the framework of a wholly owned subsidiary,
Important information
This information is such information that Bio Vitos Pharma is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on
https://news.cision.com/bio-vitos-pharma-ab/r/the-european-patent-office-epo-grants-patent-that-is-important-to-bio-vitos-pharma,c3896597
https://mb.cision.com/Main/16884/3896597/2506152.pdf
(c) 2023 Cision. All rights reserved., source